论文部分内容阅读
目的:观察祛痹镇痛方治疗类风湿关节炎(RA)的临床疗效。方法:将100例患者随机分为2组各50例,对照组口服甲氨喋呤(MTX)、柳氮磺吡啶片及美洛昔康片;治疗组在对照组的基础上加用祛痹镇痛方治疗,疗程均为3月。观察2组临床疗效,治疗前后症状、体征及实验室指标变化。结果:总有效率治疗组为88.0%,对照组为72.0%,2组比较,差异有统计学意义(P<0.05)。2组治疗后症状、体征及血沉(ESR)、C-反应蛋白(CRP)、类风湿因子(RF)、抗环瓜氨酸抗体(抗CCP)均较治疗前有不同程度改善(P<0.05);治疗组改善晨僵、握力、关节压痛数、关节肿胀数、ESR、CRP、RF、抗CCP等方面均优于对照组(P<0.05)。结论:祛痹镇痛方加西药治疗RA疗效优于单独西药治疗,值得临床推广应用。
Objective: To observe the curative effect of Qubi analgesic prescription on rheumatoid arthritis (RA). Methods: 100 patients were randomly divided into two groups of 50 cases, the control group oral methotrexate (MTX), sulfasalazine tablets and meloxicam tablets; the treatment group in the control group based on the use of cured paralysis Analgesic side treatment, treatment are March. The clinical curative effect, the symptoms and signs before and after treatment and the changes of laboratory indexes were observed. Results: The total effective rate was 88.0% in the treatment group and 72.0% in the control group. There was significant difference between the two groups (P <0.05). The symptoms, signs and ESR, CRP, RF, anti-cyclic citrullinated antibody (anti-CCP) in both groups were improved to some extent after treatment (P <0.05 ). The improvement of morning stiffness, grip strength, joint tenderness, joint swelling, ESR, CRP, RF and anti-CCP in the treatment group were better than those in the control group (P <0.05). Conclusion: Qubi analgesic prescription plus western medicine treatment of RA is superior to western medicine treatment alone, worthy of clinical application.